Trials have suggested that SaNOtize's spray killed more than 95% of the coronaviruses that cause COVID-19 in infected participants.
Early-stage clinical trials of a spray produced by SaNOtize Research & Development Corp have found that the product effectively kills coronavirus particles. The trials in Utah, Canada, and the U.K. of the nasal spray have lessened the COVID-19 viral load in the infected patients.
On March 15, 2021, the U.K. announced the nasal spray's Phase II trial results. Seventy-nine confirmed COVID-19 cases were evaluated in the trial, and it was proved that the level of high viral loads was significantly reduced through SaNOtize's immediate treatment.
The nasal spray's clinical trial proved that within 24 hours of treatment, more than 95% of the viral log was reduced, and more than 99% was reduced within 72 hours. Viral load refers to the levels of a virus found in someone's bloodstream. The randomized, double-blind, placebo-controlled Phase II trial had most patients infected with the U.K strain. In the U.K. trial, or the 7000 self-administered treatments provided earlier in Canadian clinical trials, no adverse health effects were recorded. The organization is now seeking Emergency Use Authorization from regulatory authorities in the United Kingdom and Canada.
The SaNOtize treatment eliminates COVID-19 in the upper respiratory tract, preventing it from incubating and spreading to the lungs. According to the company, the pharmacology, toxicity, and safety data for nitric oxide use in humans have been well known for decades.
A press release from Royal Holloway University, who were involved in the trials of the spray, said that it could be effective in treating mild to moderate cases of COVID-19: "The strategy is to use the Nitric Oxide spray as a multi-stage defense against infection and to provide an effective treatment for mild and moderate cases with the goal of preventing severe inflammatory response and infection of the lungs."
It added: "Scientists believe the coronavirus is transmitted via airborne droplets to the mucous membranes in the nose, where it is replicated during a three-day incubation period, damaging the nasal mucosa cells, and is then carried in nasal secretions to the lower respiratory tract, leading to the danger of fatal viral pneumonia."
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.